Table 1.
Characteristics of the included studies.
| Study, year | Country | No. of eyes | Age (year) | Sex (Male%) | Duration of MS (year) | EDSS scores | OCTA device | STROBE scores | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Control group | MS group | Control group | MS group | Control group | MS group | ||||||
| Aly et al. (2021) | Germany | 42 | 41 | 42.0 | 38.0 | 23.8 | 23.8 | 5.7 | 1.4 | OptoVue | 20 |
| Cennamo et al. (2020) | Italy | 30 | 20 | 28.2 | 29.7 | 33.3 | 30.0 | 4.0 | 2.3 | OptoVue | 19 |
| Cordon et al. (2020) | Spain | 149 | 92 | 41.8 | 41.7 | 13.4 | 13.0 | 5.0 | 2.0 | Topcon | 18 |
| Farci et al. (2020) | Italy | 29 | 91 | 52.7 | 41.5 | 65.5 | 13.2 | NA | NA | OptoVue | 18 |
| Feucht et al. (2019) | Germany | 100 | 83 | 32.0 | 30.0 | 68.0 | 69.0 | 4.1 | 1.0 | OptoVue | 20 |
| Kallab et al. (2021) | Austria | 18 | 32 | 41.0 | 43.0 | 22.2 | 25.0 | 9.0 | NA | Heidelberg | 19 |
| Khader et al. (2021) | Egypt | 10 | 20 | 30.0 | 30.9 | NA | NA | 4.3 | NA | Zeiss | 18 |
| Lanzillo et al. (2018) | Italy | 92 | 100 | 43.3 | 40.6 | 47.8 | 38.0 | 11.0 | 3.5 | OptoVue | 21 |
| Montorio et al. (2021) | Italy | 30 | 30 | 27.2 | 28.4 | 53.3 | 46.7 | NA | 1.8 | OptoVue | 20 |
| Murphy et al. (2020) | USA | 97 | 201 | 34.5 | 40.0 | 42.0 | 19.8 | 10.0 | 1.5 | Heidelberg | 20 |
| Rogaczewska et al. (2021a,b) | Poland | 40 | 77 | 37.9 | 35.2 | 15.0 | 20.0 | 8.0 | NA | Optovue | 17 |
| Ulusoy et al. (2020) | Turkey | 48 | 40 | 41.4 | 43.8 | 37.5 | 35.0 | 9.5 | 2.3 | OptoVue | 20 |
| Yilmaz et al. (2020) | Turkey | 122 | 94 | 38.6 | 38.3 | 19.7 | 17.0 | 8.2 | 1.5 | Nidek | 19 |
MS, Multiple sclerosis; EDSS, Expanded Disability Status Scale; OCTA, Optical coherence tomography angiography;NA, not available.